26 recruiting, 21 not yet recruiting, 21 unknown, 9 active not recruiting. 87 Phase 2, 4 Phase 3, 1 Phase 1.
Follow Neoadjuvant Therapy: new trials by email Literature Review of Neoadjuvant Therapy trials Research Report on Neoadjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC Nivolumab - Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 40 | 2026-11-02 | 2026-10-28 |
| Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 ) Neoadjuvant radiotherapy, ADC + PD1 monoclonal antibody - Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Peking University First Hospital | 20 | 2026-11-01 | 2026-10-28 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-28 |
| Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC Firmonertinib combined anlotinib and chemotehrapy - NSCLC (Non-small Cell Lung Cancer), EGFR | Phase 2 | Not yet recruiting | Hubei Cancer Hospital | 29 | 2026-09-21 | 2026-09-08 |
| Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks. - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2026-09-03 | 2026-10-27 |
| Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma Becotatug Vedotin (MRG003), Pucotenlimab - Oral Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 32 | 2026-09-01 | 2026-08-17 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy - Cervical Cancer, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2026-06-15 | 2026-06-01 |
| Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 49 | 2026-06-03 | 2026-10-02 |
| Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib Abemaciclib - Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 150 | 2026-04-30 | 2026-03-05 |
| Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 182 | 2026-04-20 | 2026-07-09 |
| Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy QL1706 combined with Chemotherapy - Breast Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-04-14 | 2026-09-28 |
| Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Interferon-γ, Camrelizumab - Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Hefei Cancer Hospital of the Chinese Academy of Sciences | 84 | 2026-03-20 | 2026-08-26 |
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo - Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Seventh Medical Center of PLA General Hospital | 50 | 2026-02-10 | 2026-03-10 |
| Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC fulzerasib - Resectable NSCLC, KRAS G12C Mutation | Phase 2 | Recruiting | Jianxing He | 30 | 2026-01-29 | 2026-03-25 |
| Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) short-course radiotherapy, Zanidatamab, Tisleizumab(BGB-A317) - Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tao Zhang | 70 | 2026-01-15 | 2025-11-24 |
| Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma sintilimab combined with bevacizumab biosimilar - Hepatocellular Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Sun Yat-sen University | 37 | 2026-01-14 | 2026-01-16 |
| Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer Adebrelimab, albumin-bound paclitaxel, Gemcitabine - Pancreatic Cancer, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Jinling Hospital, China | 30 | 2025-11-30 | 2025-11-18 |
| Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC QL1706 Combined With Lenvatinib - Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 25 | 2025-11-21 | 2026-02-05 |
| A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab - Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer | Phase 2 | Not yet recruiting | Yantai Yuhuangding Hospital | 52 | 2025-10-30 | 2025-10-01 |
Showing 20 of 87. Sign in to see all of them.
Breast Neoplasms (8) · Esophageal Squamous Cell Carcinoma (7) · Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Rectal Neoplasms (4) · Stomach Neoplasms (4) · Colonic Neoplasms (3) · Turcot syndrome (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Renal Cell (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Prostatic Neoplasms (2) · Triple Negative Breast Neoplasms (2)
Neoplasms (62) · Neoplasms by Site (60) · Digestive System Diseases (28) · Digestive System Neoplasms (27) · Gastrointestinal Diseases (26) · Gastrointestinal Neoplasms (25) · Neoplasms by Histologic Type (20) · Neoplasms, Glandular and Epithelial (19) · Carcinoma (18) · Head and Neck Neoplasms (14) · Carcinoma, Squamous Cell (12) · Intestinal Diseases (12) · Intestinal Neoplasms (12) · Colonic Diseases (10) · Breast Diseases (9)
Neoadjuvant Therapy (10) · Oxaliplatin (9) · Carboplatin (8) · Capecitabine (6) · Drug Therapy (6) · Surgical Procedures, Operative (6) · tislelizumab (6) · toripalimab (6) · Albumin-Bound Paclitaxel (5) · Cisplatin (5) · camrelizumab (5) · Esophagectomy (4) · Injections (4) · Radiotherapy (4) · S 1 (combination) (4)
Fudan University (8) · Sun Yat-sen University (8) · Second Affiliated Hospital, Zhejiang University, School of Medicine (6) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · First Affiliated Hospital of Zhejiang University (2) · Hongqian Guo (2) · Peking University First Hospital (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Tianjin Medical University Second Hospital (2) · West China Hospital (2) · Zhejiang University (2) · Army Medical Center of PLA (1)
China (68) · South Korea (2) · Belgium (1) · Canada (1) · Denmark (1) · Egypt (1) · Italy (1) · Lithuania (1) · Taiwan (1) · United States (1)
Weilin Wang (3) · Jianan Wang (2) · Audrius Dulskas, PhD (1) · Barbara Smith, MD, PhD (1) · Bin Wang (1) · Feng Cheng, MD (1) · Frances Wright, MD (1) · Gaoping Gaoping, doctor (1) · Gong Chang, doctor (1) · Hailong Hu, PhD (1) · Hongzhi Wang (1) · Jianwei Zhou, PhD (1)
PMID 29606109, PMID 34241629, PMID 34606846, PMID 34688374, PMID 35219300, PMID 35574368, PMID 35764956, PMID 35902798, PMID 36922805, PMID 37409565, PMID 38553594, PMID 38618203, PMID 38853265, PMID 39978682, PMID 40348946, PMID 41164763, PMID 41423619, PMID 41922688, PMID 42114951, PMID 42320986, PMID 42385761
2016 (1), R01CA212138 (1)